<?xml version="1.0" encoding="UTF-8"?>
<p>3-chymotrypsin-like protein (synonyms: coronavirus main protease, M
 <sup>pro</sup>, 3CL
 <sup>pro</sup>) of SARS-CoV-2 is a 33.8 kDa homodimeric protein (306 aa) that belongs to the cysteine protease class (possibly from C30 family and PA clan).
 <xref rid="B68" ref-type="bibr">
  <sup>68</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B69" ref-type="bibr">
  <sup>69</sup>
 </xref> This enzyme catalyses the hydrolysis of peptide bonds of polyproteins (possibly E.C. 3.4.22.69) at sites whose amino acid sequences generally follow the pattern Leu-Gln* (Ser, Ala, Gly) (*marks the cleavage site).
 <xref rid="B70" ref-type="bibr">
  <sup>70</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B71" ref-type="bibr">
  <sup>71</sup>
 </xref> M
 <sup>pro</sup> is part of pp1a/pp1ab polyproteins (Nsp5).
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref> During polyproteins translation, M
 <sup>pro</sup> suffers autolytic cleavage and is released from its polyprotein precursor, reaching a mature state that cleaves pp1a/pp1ab at no less than 11 sites downstream of the Nsp4 coding region.
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B68" ref-type="bibr">
  <sup>68</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B70" ref-type="bibr">
  <sup>70</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B72" ref-type="bibr">
  <sup>72</sup>
 </xref> Each protomer of SARS-CoV-2 M
 <sup>pro</sup> is divided into three domains: chymotrypsin and picornavirus 3C protease-like I and II domains, composed by antiparallel β-barrel structures, and domain III which contains five α-helices arranged into an antiparallel globular cluster responsible for protease dimerisation (
 <xref ref-type="fig" rid="f3">Fig. 3</xref>A). Domains II and III are connected by a long loop, where lies a cleft that serves as a substrate binding site and where catalysis occurs using the Cys
 <sup>145</sup>-His
 <sup>41</sup> dyad (
 <xref ref-type="fig" rid="f3">Fig. 3</xref>B).
 <xref rid="B68" ref-type="bibr">
  <sup>68</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B70" ref-type="bibr">
  <sup>70</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B73" ref-type="bibr">
  <sup>73</sup>
 </xref> M
 <sup>pro</sup> has been widely explored in drug discovery campaigns using experimental and/or computational approaches.
 <xref rid="B68" ref-type="bibr">
  <sup>68</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B73" ref-type="bibr">
  <sup>73</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B74" ref-type="bibr">
  <sup>74</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B75" ref-type="bibr">
  <sup>75</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B76" ref-type="bibr">
  <sup>76</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B77" ref-type="bibr">
  <sup>77</sup>
 </xref> Moreover, M
 <sup>pro</sup> has no human homologue, which reduces the chances of toxic effects of a given inhibitor.
 <xref rid="B68" ref-type="bibr">
  <sup>68</sup>
 </xref> Potential SARS-CoV-2 M
 <sup>pro</sup> inhibitors include FDA-approved antivirals, such as inhibitors of HIV-1 [e. g., lopinavir (1) /ritonavir (2)] and HCV [e.g., boceprevir (3)] proteases, as well as antineoplastic [e.g. carmofur (4)] and antibacterial [e.g., doxycycline (5)] drugs.
 <xref rid="B73" ref-type="bibr">
  <sup>73</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B78" ref-type="bibr">
  <sup>78</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B79" ref-type="bibr">
  <sup>79</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B80" ref-type="bibr">
  <sup>80</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B81" ref-type="bibr">
  <sup>81</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B82" ref-type="bibr">
  <sup>82</sup>
 </xref> Chemical structures for compounds 1-14 are shown in 
 <xref ref-type="fig" rid="f4">Fig. 4</xref>.
</p>
